Anti-KDM5B monoclonal antibody
The Alternative Names of target: KDM5B,Lysine-specific demethylase 5B,Cancer/testis antigen 31 (CT31), Histone demethylase JARID1B, Jumonji/ARID domain-containing protein 1B, PLU-1, Retinoblastoma-binding protein 2 homolog 1 (RBP2-H1), [histone H3]-trimethyl-L-lysine(4) demethylase 5B,CT31,PLU1,PUT1,MRT65,PLU-1,JARID1B,PPP1R98,RBP2-H1,RBBP2H1A
Pre-made anti-KDM5B monoclonal antibody (mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.
Go
to KDM5B products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T56871-Ab-1/ GM-Tg-hg-T56871-Ab-2 | Anti-Human KDM5B monoclonal antibody | Human |
GM-Tg-rg-T56871-Ab-1/ GM-Tg-rg-T56871-Ab-2 | Anti-Rat KDM5B monoclonal antibody | Rat |
GM-Tg-mg-T56871-Ab-1/ GM-Tg-mg-T56871-Ab-2 | Anti-Mouse KDM5B monoclonal antibody | Mouse |
GM-Tg-cynog-T56871-Ab-1/ GM-Tg-cynog-T56871-Ab-2 | Anti-Cynomolgus/Rhesus macaque KDM5B monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T56871-Ab-1/ GM-Tg-felg-T56871-Ab-2 | Anti-Feline KDM5B monoclonal antibody | Feline |
GM-Tg-cang-T56871-Ab-1/ GM-Tg-cang-T56871-Ab-2 | Anti-Canine KDM5B monoclonal antibody | Canine |
GM-Tg-bovg-T56871-Ab-1/ GM-Tg-bovg-T56871-Ab-2 | Anti-Bovine KDM5B monoclonal antibody | Bovine |
GM-Tg-equg-T56871-Ab-1/ GM-Tg-equg-T56871-Ab-2 | Anti-Equine KDM5B monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. |
GM-Tg-hg-T56871-Ab-1/ GM-Tg-hg-T56871-Ab-2;
GM-Tg-rg-T56871-Ab-1/ GM-Tg-rg-T56871-Ab-2;
GM-Tg-mg-T56871-Ab-1/ GM-Tg-mg-T56871-Ab-2; GM-Tg-cynog-T56871-Ab-1/ GM-Tg-cynog-T56871-Ab-2; GM-Tg-felg-T56871-Ab-1/ GM-Tg-felg-T56871-Ab-2; GM-Tg-cang-T56871-Ab-1/ GM-Tg-cang-T56871-Ab-2; GM-Tg-bovg-T56871-Ab-1/ GM-Tg-bovg-T56871-Ab-2; GM-Tg-equg-T56871-Ab-1/ GM-Tg-equg-T56871-Ab-2 |
Products Name | Anti-KDM5B monoclonal antibody |
Format | mab |
Target Name | KDM5B |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) |
IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-KDM5B monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data/case study
Click to get more Data/Case study about the product.
About Gmab
GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.
Comments
No comments yet.